Antidepressant News and Research

RSS

Antidepressants are medicines that treat depression. Your doctor can prescribe them for you. They can improve your mood, sleep, appetite and concentration. It may take several weeks for them to help. There are several types of antidepressants. You and your doctor may have to try several before finding what works best for you.

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

A new study sponsored by the Substance Abuse and Mental Health Services Administration outlines the conditions that physicians around the country reported treating with psychiatric drugs such as antipsychotics, antidepressants, and anti-anxiety drugs.

23 Mar 2010

Dow Jones reports on side effects of Labopharm's once-daily version of Trazodone, stock falls by 5%

After Canadian specialty pharmaceutical company Labopharm received FDA approval for its once-daily version of antidepressant Trazodone, Dow Jones Newswires reported that it will be difficult to convince prescribers to switch from less expensive generic versions. Dow Jones found that when compared, the side effects of Labopharm's drug fare no better than the generic versions that dominate the market.

22 Mar 2010

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Hercules Technology Growth Capital, Inc., the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed over $52.0 million in structured debt financing to new and existing portfolio companies.

19 Mar 2010

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

11 Mar 2010

Risk-free psychological treatment can be better alternative to drugs in treating women with low sexual desire

According to the Journal of Sexual Medicine, people who engage in regular sexual activity gain several health benefits, such as longer lives, healthier hearts, lower blood pressure, and lower risk of breast cancer. However, approximately 33 percent of women may not receive these benefits due to low sexual desire.

10 Mar 2010

Common psychiatric illnesses: Free online questionnaire helps doctors screen patients

A one-page, 27-item questionnaire that is available free online is a valid and effective tool to help primary care doctors screen patients for four common psychiatric illnesses, a study led by University of North Carolina at Chapel Hill researchers concludes.

9 Mar 2010

Moderating treatment response in depression: Role of personality factors

A study published in the current issue of Psychotherapy and Psychosomatics addresses the role of personality factors in moderating treatment response in depression.

8 Mar 2010

Association between depression and obesity bidirectional

Obesity appears to be associated with an increased risk of depression, and depression also appears associated with an increased risk of developing obesity, according to a meta-analysis of previously published studies in the March issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

2 Mar 2010

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Conventional antidepressant treatments generally require three to four weeks to become effective, thus the discovery of treatments with a more rapid onset is a major goal of biological psychiatry. The first drug found to produce rapid improvement in mood was the NMDA glutamate receptor antagonist, ketamine.

1 Mar 2010

New research using MRI shows that childhood stress can lead to structural brain changes

New research using magnetic resonance imaging (MRI) shows that childhood stress such as abuse or emotional neglect, in particular when combined with genetic factors, can result in structural brain changes, rendering these people more vulnerable to developing depression. The study led by scientists at Trinity College Dublin has just been published in the international scientific journal, Neuropsychopharmacology.

25 Feb 2010

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Labopharm Inc. today reported its financial results for the fourth quarter and fiscal year ended December 31, 2009. All figures are in Canadian dollars unless otherwise stated.

25 Feb 2010

Combination therapies effective for treating depression

Even after she left her alcoholic, abusive husband behind, Patrice, a nurse in Florida, couldn't summon the energy to keep her house straight, couldn't sleep.

24 Feb 2010

Strategies to reduce inappropriate treatment by clinicians

Clinicians may use one of several approaches to deny patient requests for an inappropriate treatment while preserving the physician-patient relationship, according to a report in the February 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

23 Feb 2010

VR technology plays important role in treating patients with PTSD

Posttraumatic stress disorder (PTSD) threatens to overload healthcare and social support systems worldwide as the number of cases rises and existing treatments are not sufficiently effective.

12 Feb 2010

MHQP: Massachusetts primary care physicians achieve measurable improvements in health care quality

Massachusetts primary care physicians continue to achieve measurable improvements in important aspects of health care quality as reported by Massachusetts Health Quality Partners (MHQP). Today, the organization released its sixth annual Quality Insights: Clinical Quality in Primary Care report, comparing the performance of more than 150 medical groups across the state.

11 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Antidepressant News and Research

Further Reading

SAMHSA study shows how psychiatric drugs prescribed for medical conditions

Dow Jones reports on side effects of Labopharm's once-daily version of Trazodone, stock falls by 5%

Hercules Technology Growth Capital commits over $52.0M in structured debt financing

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

Risk-free psychological treatment can be better alternative to drugs in treating women with low sexual desire

Common psychiatric illnesses: Free online questionnaire helps doctors screen patients

Moderating treatment response in depression: Role of personality factors

Association between depression and obesity bidirectional

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

New research using MRI shows that childhood stress can lead to structural brain changes

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Combination therapies effective for treating depression

Strategies to reduce inappropriate treatment by clinicians

VR technology plays important role in treating patients with PTSD

MHQP: Massachusetts primary care physicians achieve measurable improvements in health care quality

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Breast cancer patients taking antidepressant paroxetine at the same time as tamoxifen are at increased risk of death

Study highlights the importance of effective therapy to fight depression

Study suggests molecules and pathways in mood regulation and circadian rhythms are intertwined

New class of compound could become effective antidepressant with minimal side effects

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News